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Abstract
Background: The glyoxalase pathway, which includes two enzymes, glyoxalase 1 and 2 (Glo1 and Glo2), is a
ubiquitous cellular system responsible for the removal of cytotoxic methylglyoxal produced during glycolysis.
Protozoan parasites, including Toxoplasma gondii (T. gondii) tachyzoites, produce methylglyoxal because of
increased glycolytic fluxes. A Glo1 inhibitor such as curcumin could be considered a drug candidate for
anti-protozoan, anti-inflammatory, and anti-cancer therapy.
Methods: The T. gondii Glo1 gene (TgGlo1) was cloned and the recombinant protein was produced. Enzyme
kinetics of TgGlo1 and five mutants were evaluated by adding methylglyoxal and glutathione to a reaction
mixture. Finally, the inhibitory effects of various concentrations of curcumin on recombinant TgGlo1 were
evaluated using in vitro cultures of T. gondii.
Results: Active recombinant TgGlo1 was successfully produced and the active sites (E166 and E251) of TgGlo1
were verified by point mutagenesis. Curcumin at the tested doses inhibited the enzymatic activity of recombinant
TgGlo1 as well as the parasitic propagation of in vitro-cultured T. gondii. The Ki and IC50 were 12.9 ± 0.5 μM
and 38.3 ± 0.9 μM, respectively.
Conclusion: The inhibitory effect of curcumin on the enzymatic activity of TgGlo1 and parasitic propagation
of T. gondii could be explored in the potential development of a potent drug for the treatment of toxoplasmosis.
However, considering the fact that curcumin is known to have many effects on other molecules in the micromolar
range, further elucidation of curcumin’s direct inhibition of the glyoxalase system of T. gondii will be needed.
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Background
Toxoplasma gondii is a major pathogen of a broad range
of warm-blooded animals, including humans, livestock,
and domestic pets [1, 2]. The parasite is of clinical im-
portance in causing devastating disease in the developing
fetus, as well as opportunistic infections in immunocom-
promised and transplant patients [3]. In human hosts, the
parasites differentiate into tachyzoites and bradyzoites,
which display distinct physiological features. The dormant
bradyzoites show an extremely reduced growth rate, close
to complete arrest of the cell cycle, while tachyzoites rap-
idly duplicate in the acute phase of infection. The tachy-
zoite stage constitutes an effective pathway for nutrient
acquisition and energy metabolism for the parasite.
The glyoxalase pathway is the ubiquitous cellular
system responsible for the removal of methylglyoxal,
a cytotoxic reactive carbonyl compound produced in
many organisms as a consequence of central metab-
olism [4–6]. During glycolysis, methylglyoxal is pro-
duced by imperfect degradation of glucose because of
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the spontaneous elimination of phosphate from dihy-
droxyacetone-phosphate or glyceraldehyde-3-phosphate [7].
Plasmodium species, which are apicomplexan para-
sites closely related to T. gondii, also show increased
methylglyoxal production [8, 9]. Therefore, the in-
creased glycolytic fluxes in T. gondii tachyzoites
would suggest that these parasites require an efficient
detoxification system for removal of harmful methyl-
glyoxal. While there are several reports of studies fo-
cusing on the glyoxalase system of Plasmodium
species as a potential drug target, no such study has
been reported in T. gondii to date [10].
Curcumin is a polyphenol derivative isolated from the
plant Curcuma longa. By interacting with more than 30
proteins, curcumin exhibits anti-inflammatory, anti-
oxidant, anti-viral, and anti-infectious activity in exten-
sive studies conducted over the past several decades
[11]. Curcumin was recently reported to be a non-
glutathione inhibitor of small homodimeric mammalian
glyoxalase 1 (Glo1) [12]. In addition, curcumin showed
in vitro and in vivo anti-trypanosomal effects in Trypa-
nosoma evansi as well as anti-malarial effects in Plasmo-
dium falciparum cultures and in Plasmodium berghei in
vivo [13–15]. In these studies, the effects of curcumin
appeared to target the glyoxalase system, as suggested by
its inhibition of the enzymatic activities of Glo1 of the
Trypanosoma and Plasmodium species.
In the present study, we identified a functional Glo1 of
T. gondii (TgGlo1) and evaluated active sites of TgGlo1
by point mutagenesis and enzyme kinetic analysis. In
addition, inhibitory effects of curcumin against the en-
zymatic activity of recombinant TgGlo1 and parasite
growth in T. gondii cultures were analyzed.
Methods
Parasites and cell cultures
The T. gondii RH and green fluorescent protein-
expressing RH (GFP-RH) strains used in this study were
maintained in Vero cells and human foreskin fibroblasts
(HFFs) at 37 °C and 5 % CO2 in Dulbecco’s modified
eagle medium (DMEM, Sigma-Aldrich, St. Louis, MO
USA) supplemented with 10 % heat-inactivated fetal bo-
vine serum (FBS).
Cloning of the TgGlo1 gene
TgGlo1 was amplified from T. gondii cDNA using the
primers listed in Table 1. The specific primers were de-
signed according to the TgGlo1 sequence in ToxoDB
(accession number, TGGT1_248400). The amplified
polymerase chain reaction (PCR) products were ex-
tracted using the QIAquick gel extraction kit (QIAGEN,
Hilden, Germany) and then digested with EcoRI and
HindIII. The digested DNA was inserted between the
EcoRI and HindIII sites of the expression vector pRSETb
(Invitrogen, Carlsbad, CA, USA). Thereafter, accurate
gene insertion was confirmed by digestion with restric-
tion enzymes and sequencing.
Generation of TgGlo1 point mutants
Mutations of the TgGlo1 gene (E92Q, E166Q, R188E,
E251Q, E324Q, E92Q/E324Q, and E166Q/E251Q) were
introduced by PCR using Ex Taq polymerase (Takara,
Shiga, Japan) with mutated primers (Table 1) and the
TgGlo1 gene as a template. The mutant genes were
subcloned into the pGEM T-easy vector (Promega,
Madison, WI, USA) and subsequently confirmed by
sequencing both strands. The mutated genes were sub-
cloned into the pRSETb vector (Invitrogen) for recom-
binant protein expression.
Expression and protein purification of wild-type and
mutants of TgGlo1
The protein expression was performed as previously de-
scribed by Deponte et al. [16] with modifications. The
pRSETb constructs of the wild-type and mutant TgGlo1
genes were expressed in E. coli strain BL21(DE3)pLysS
(Invitrogen). Transformation of the respective plasmid
to competent cells was performed before each expres-
sion, and the bacteria were precultured overnight at 37 °C.
The preculture was added to fresh medium (10 g/L yeast
extract, 5 g/L peptone, 10 g/L NaCl, 2 g/L MgSO4 · 7H2O,
10 mM 3-(N-morpholino) propanesulfonic acid (MOPS)/
NaOH at pH 7.5, and 100 mg/L ampicillin) and grown at
37 °C. After induction by 0.1 mM isopropyl β-D-1-thio-
galactopyranoside and overnight culturing, 3 l of cul-
ture cells were harvested by centrifugation (10 min,
12,000 × g) and resuspended in 20 mL of buffer con-
taining 10 mM MOPS/NaOH (pH 7.8), lysozyme,
DNase I, and 50 μM phenylmethanesulfonyl fluoride.
Then, the resuspended cells were sonicated at 4 °C and
Table 1 Primers used for amplification of TgGlo1 gene and
generation of point mutations of TgGlo1
Gene Primer Sequence
TgGlo1 Forward 5′-GGGGAATTCATGTCCAGAAGTTTGCCC-3′
Reverse 5′-GGGAAGCTTTTACTTCTTTGAAAGGAACG-3′
E92Q Forward 5′-GGGACGTGCTTGCAACTCACTCACAATC-3′
Reverse 5′-GATTGTGAGTGAGTTGCAAGCACGTCCC-3′
E166Q Forward 5′-GGATACTGGATACAATTGGTTTCTCGG-3′
Reverse 5′-CCGAGAAACCAATTGTATCCAGTATCC-3′
R188E Forward 5′-CAGACGATGATTGAAATCAAAGATCCG-3′
Reverse 5′-CGGATCTTTGATCCGAATCATCGTCTG-3′
E251Q Forward 5′-CAGCCTGTATTACAACTCACACACAATCAC-3′
Reverse 5′-GTGATTGTGTGTGAGTTGTAATACAGGCTG-3′
E324Q Forward 5′-GGATATAGCATCCAACTGATTCAG-3′
Reverse 5′-CTGAATCAGTTGGATGCTATATCC-3′
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centrifuged for 30 min at 12,000 × g. The supernatant
was applied to an S-hexylglutathione-agarose column
(Sigma-Aldrich), which was equilibrated with buffer
containing 10 mM MOPS/NaOH (pH 7.8). After wash-
ing with eight column volumes of 10 mM MOPS/
NaOH and 200 mM NaCl (pH 7.8), the recombinant
enzyme was eluted by three column volumes of 5 mM
S-hexylglutathione (pH 7.8). The eluent was loaded
onto a nickel-nitrilotriacetic acid column (Qiagen) and
eluted with buffer containing 125 mM imidazole
(pH 8.0). The purity of rTgGlo1 was confirmed by SDS-
PAGE (Additional file 1: Figure S1).
Production of antiserum against TgGlo1
The antiserum specific to TgGlo1 was produced by im-
munizing five 6-week-old female ICR mice (CLEA Japan,
Inc., Tokyo, Japan). The purified rTgGlo1 (200 μg) were
emulsified with an equal volume of complete Freund’s
adjuvant (Difco Laboratories, Detroit, MI, USA), and
then intraperitoneally injected. Two additional boosters
with 100 μg of each antigen with incomplete Freund’s
adjuvant (Difco) were intraperitoneally administered at
2-week intervals. The mice were bled 2 weeks after the
last booster, and serum samples were stored at −30 °C.
The specificity of anti-rTgGlo1 serum was evaluated by
western blot as shown in Additional file 1: Figure S2.
Steady-state kinetics
The steady-state kinetics of the recombinant enzymes were
monitored spectrophotometrically, using a thermostatted
Hitach U-2001 visible spectrophotometer. Experiments to
determine Km values were performed as described previ-
ously [16]. Stock solutions of 10 mM glutathione (GSH;
Sigma-Aldrich) in assay buffer containing 50 mM MOPS/
NaOH (pH 7.0) were freshly prepared before each experi-
ment. For the desired concentration of hemithioacetal, con-
centrations of methylglyoxal and GSH in 1 mL of the assay
mixture were calculated using the following equation.
Kd ¼ 3 mM
¼ methylglyoxal½  GSH½ ð Þ= hemithioacetal½ 
The calculated concentrations of free GSH after 5 min
of preincubation and hemithioacetal were 0.1 mM and
5–500 μM, respectively. After the addition of enzyme,
the formation of S-D-lactoylglutathione was measured
spectrophotometrically at 240 nm (ε = 3.37 mM−1cm−1).
The final assay concentration of the wild-type enzyme
and mutants was 5–200 nM. The kinetic data of the ini-
tial reaction velocities were plotted according to the
Lineweaver-Burk equation using the program SigmaPlot
10.0 (Systat Software Inc., San Jose, CA, USA).
Enzymatic activity inhibition assays of curcumin
The curcumin used for this assay was purchased from
Sigma-Aldrich. Enzymatic activity of recombinant
TgGlo1 was monitored at 30 °C using a thermostatted
spectrophotometer. The TgGlo1 activity was determined
at 240 nm by measuring the conversion of the hemi-
thioacetal (the product of methylglyoxal and GSH) into
S-D-lactoylglutathione (ε = 3.37 mM−1cm−1). Stock solu-
tions of 10 mM curcumin in assay buffer (50 mM
MOPS/NaOH pH 7.0) and less than 10 mM curcumin
in methanol were freshly prepared before each experi-
ment. The curcumin was added after the first 4 min of
the 5-min preincubation period and the reaction was ini-
tiated by adding 5 nM of enzyme.
Growth inhibition assay of curcumin-treated T. gondii
Growth inhibition assay was performed following previ-
ously described methods with modifications [17–19]. In-
hibition of parasite growth by curcumin was determined
by counting the number of vacuoles containing 1, 2, 4,
8, or more than 16 tachyzoites. To investigate the effects
of curcumin exposure on parasites, HFFs in 96-well
plates were infected for 4 h and then treated with vehicle
or decreasing concentrations (25, 15, 10, 5, 2.5, 1, and
0.1 μM) of curcumin for 48 h. Plates were harvested and
analyzed by counting the number of vacuoles with dif-
ferent dividing stages of tachyzoites. In addition, in order
to determine the 50 % inhibitory concentration (IC50) of
curcumin against T. gondii cultures, HFFs infected with
T. gondii expressing GFP were counted under a micro-
scope. The IC50 represents the concentration of curcu-
min that was required for inhibition of 50 % of T. gondii
proliferation in the HFF.
Ethics statement
This study and all procedures were approved by the
Animal Care and Use Committee of Obihiro University of
Agriculture and Veterinary Medicine, Japan. The ex-
perimental animals were housed, fed, and given clean
drinking water in accordance with the stipulated rules
for the Care and Use of Research Animals Promulgated
by Obihiro University of Agriculture and Veterinary
Medicine, Japan.
Results and discussion
Characterization of T. gondii glyoxalase 1
TgGlo1 was amplified from cDNA of a T. gondii RH
strain and contained a single open reading frame of
1008 nucleotides encoding a polypeptide of 336 amino
acid residues. The sequence of TgGlo1 was identical to
that previously reported (GenBank accession no.
EPR63516). The purity of rTgGlo1 was confirmed by
SDS-PAGE (Additional file 1: Figure S1). Two putative
glyoxalase domains were identified at 20–167 and 181–325
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amino acids, by an open-sourced gene analysis program,
SMART (http://smart.embl-heidelberg.de/). TgGlo1 shared
homology with Glo1 of Neospora caninum (90 %), Eimeria
acervulina (64 %), Eimeria tenella (61 %), and P. falcip-
arum (50 %). No signal peptide was predicted for TgGlo1
by SMART, indicating that it is likely a cytosolic protein.
This notion was further supported by the immunofluores-
cence assay with antiserum against TgGlo1 using confocal
microscopy, which revealed that TgGlo1 was located
in the cytoplasm of T. gondii (Fig. 1), while pre-
immune serum did not react with T. gondii parasites
(Additional file 1: Figure S3).
Evaluation of enzyme active sites of T. gondii glyoxalase 1
In order to evaluate the enzymatic activity of recombin-
ant TgGlo1, the calculated concentrations of methyl-
glyoxal and GSH were mixed with rTgGlo1. As shown in
Fig. 2, the plot for enzymatic activity of rTgGlo1 dis-
played a curved line and biphasic pattern. Therefore, re-
gression plots were drawn in biphase (Fig. 2; 1/[S] = less
than 40 μM and 1/[S] = greater than 40 μM). The Km of
phase 1 (Km1, 1/[S] = less than 40 μM) and phase 2 (Km2,
1/[S] = greater than 40 μM) of rTgGlo1 was 10.0 ± 0.6
and 38.6 ± 1.5 μM, respectively (Table 2). Subsequently,
generating seven mutants at glutamate residues were
tried by PCR, selected based on the active sites of P. fal-
ciparum Glo1 [16]. The conserved glutamate residues of
Glo1 were previously reported to function in acid–base
catalysis during substrate enediolate formation and
reprotonation [20, 21]. Five mutants (E92Q, E166Q,
R188E, E251Q, and E166Q/E251Q) were successfully
generated; however, E324Q and E92Q/E324Q mutants
were not prepared despite several trials. The five mu-
tants were evaluated in enzyme activity assays and the
enzyme kinetic plots of two mutants also displayed a bi-
phasic pattern as shown in Table 2 and Fig. 2. The Km
values of mutants were compared to that of wild-type
TgGlo1, and E166Q and E251Q mutants showed higher
Km values. Furthermore, Km of the paired mutants
(E166Q/E251Q) showed the highest value. In addition,
Kcat of the paired mutants was 2–10-fold lower than that
of wild-type enzyme. These results indicate that the glu-
tamate residues located at positions 166 and 251 are
crucial for enzymatic activity. In P. falciparum Glo1, the
glutamate residue located on 345 amino acid was also
reported to be the crucial functional active site. How-
ever, we did not succeed in producing the E324Q mu-
tant of TgGlo1. Our results suggest that, the glutamate
residues located on 166 and 251 amino acids of TgGlo1
are functional active sites of TgGlo1. The P. falciparum
Glo1 was reported to possess two functionally paired
glutamate residues located at positions 91/345 and 272/
161 [16]. As shown in Table 2, the glutamate residues lo-
cated on 166 and 251 amino acids of TgGlo1 would be
functionally coupled. However, it is not clear if glutam-
ate residues on 92 and 345 amino acids are functionally
Fig. 1 Immunofluorescence microscopy analysis. The specific reaction of the rTgGlo1 and mouse anti-rTgGlo1 serum is green and the nuclei are
red. Merged image of fluorescent green reactivity and red PI staining of nuclei with phase-contrast images of the parasites
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paired, because of the lack of E345Q mutant production.
To further evaluate the structural interaction of the resi-
dues, studies elucidating the chemical structure of
TgGlo1 will be required.
Inhibition of T. gondii glyoxalase 1 by curcumin
Curcumin has been reported to have various pharmaco-
logical properties including anti-inflammatory, anti-
infectious, and anti-carcinogenic [22]. A number of
studies have proposed targets for the pharmacological
effects including, transcription factors, enzymes, cyto-
kines, and cell receptors. Glo1 has been considered one
of the targets of curcumin in previous studies [12, 17].
Curcumin acts by mimicking hemithioacetal, the enedio-
late reaction intermediate between methylglyoxal and
GSH. Therefore, we investigated the inhibitory effects of
curcumin on the enzymatic activity of rTgGlo1 by ana-
lyzing the steady-state kinetics at decreasing concentra-
tions of substrate and curcumin. As shown in Fig. 3a,
Lineweaver-Burk plots indicate competitive inhibition
with a constant maximum reaction velocity. The inhibi-
tory effects were consistent in various timings of curcumin
addition, from 1 to 4 min (data not shown). Curcumin has
a similar structure to hemithioacetal, and it appears that
curcumin directly interacts with the active site of TgGlo1.
In addition, the Ki value of curcumin against rTgGlo1 was
12.9 ± 0.5 μM, and curcumin inhibition became insignifi-
cant at substrate concentrations greater than 125 μM as
shown in Additional file 1: Figure S4. Moreover, the en-
zymatic activity of rTgGlo1 was not completely inhibited
by 50 μM curcumin.
We also investigated the effects of curcumin in in vitro
cultures of T. gondii. The number of vacuoles with more
than 16 parasites was remarkably decreased at concen-
trations higher than 5 μM (Fig. 3b). Specifically, a few
vacuoles with many parasites (more than 8) were ob-
served in the cultures treated with 10 μM curcumin,
compared to control cultures without curcumin (Fig. 3b).
Fig. 2 Steady-state kinetics of wild-type rTgGlo1 and five mutants, E92Q, E166Q, R188E, E251Q, and E166Q/E251Q. Measurements are expressed
as the mean of three independent experiments. The values for wild-type rTgGlo1, E92Q, and R188E were obtained from two phases (phase 1, 1/
[S] = less than 40 μM; phase 2, 1/[S] = greater than 40 μM)
Table 2 Enzyme kinetics of recombinant TgGlo1 proteins: a wild type and mutants produced by point-mutagenesis on active sites
of TgGlo1
E92Q R188E rTgGlo1
Phase 1 Phase 2 E166Q Phase 1 Phase 2 E251Q E166Q /E251Q Phase 1 Phase 2
Km (μM) 11 ± 2.1 42 ± 5.2 173 ± 8.0 14 ± 2.3 42 ± 2.1 94 ± 3.2 190 ± 5.2 10.0 ± 0.6 38.6 ± 1.5
Kcat (s
−1) 159 ± 16 76 ± 9 93 ± 4 654 ± 12 254 ± 20 100 ± 17 114 ± 9 1305 ± 38 257 ± 11
(Phase 1, 1/[S] = less than 40 μM; Phase 2, 1/[S] = more than 40 μM)
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Fig. 3 Inhibition of TgGlo1 enzymatic activity and parasite growth of T. gondii by curcumin. a Inhibitory effects of curcumin on steady-kinetics of
rTgGlo1. The purified rTgGlo1 was incubated with decreasing concentrations of curcumin and enzymatic activity was recorded. Enzymatic activity
of rTgGlo1 decreased in a dose-dependent manner after treatment with curcumin. b Curcumin inhibition study in T. gondii cultures. T. gondii
propagation was inhibited with concentrations of curcumin higher than 5 μM. c Curcumin inhibition study in dose–response experiments with
T. gondii. Proliferation of T. gondii was decreased in a dose-dependent manner after treatment with curcumin
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When a broad range of curcumin concentrations (1–
100 μM) was tested, the growth of T. gondii parasites was
inhibited in a dose-dependent manner (Fig. 3c). The IC50
of curcumin in T. gondii was 38.3 ± 0.9 μM. These results
suggest that curcumin may kill the T. gondii parasites by
interfering with their differentiation. However, it is diffi-
cult to conclude that the growth inhibitory effect of curcu-
min on T. gondii was solely the result of targeting TgGlo1,
because many effects of curcumin have been reported in
the micromolar range [13]. To clarify this point, further
evaluation of the direct inhibitory effects of curcumin on
the glyoxalase system of T. gondii will be needed.
Rapidly propagating cells, including cancer cells and
protozoan parasites, consume more glucose and have in-
creased glycolytic flux compared to normal cells, resulting
in intracellular levels of methylglyoxal that are toxic to the
respective cells [23]. Methylglyoxal has been reported to
modify the function of distinct proteins including heat
shock protein 27, NF-kB, and glyceraldehyde 3-phosphate
dehydrogenase in mammalian cells [24, 25]. Modulation of
the proteins causes cell death by depletion of ATP, induc-
tion of apoptosis, and increases in levels of reactive oxygen
species [26]. In order to remove the toxic methylglyoxal,
the cells increase expression of Glo1. Therefore, inhibitors
of Glo1 have potential as chemotherapeutic agents.
Conclusion
In the current study, a cytosolic TgGlo1 was identified
and its active sites (E166 and E251) were verified by
point mutagenesis. Curcumin inhibited the enzymatic
activity of recombinant TgGlo1 and parasite propagation
in cultures of T. gondii. However, considering the fact
that curcumin is known to have many effects on other
molecules in the micromolar range, further elucidation
of curcumin’s direct inhibition of the glyoxalase system
of T. gondii will be needed.
Additional file
Additional file 1: Figure S1. SDS-PAGE of recombinant TgGlo1-His
protein (12 % SDS-PAGE gel). Lane M, low molecular mass marker; lane A,
recombinant TgGlo1-His protein; lane B, nickel-nitrilotriacetic acid resin after an
elution of recombinant TgGlo1-His protein; lane C, Escherichia coli expressing
recombinant TgGlo1-His after sonication. Figure S2. Western blot analysis of
recombinant and native TgGlo1. Lane A, recombinant TgGlo1 reacted with
anti-TgGlo1 mouse serum; lane B, Toxoplasma gondii lysate reacted with anti-
TgGlo1 mouse serum; lane C, T. gondii lysate reacted with pre-immunized
mouse serum. Figure S3. Immunofluorescence staining and confocal
microscopy for pre-immunized mouse serum. Pre-immunized mouse
serum did not react with Toxoplasma gondii parasites. Merged image of
fluorescent green reactivity and red PI staining of nuclei with phase-contrast
images of the parasites showed only red-stained nuclei. Figure S4. The
inhibitory effects of curcumin on enzymatic activity of rTgGlo1 with different
concentrations of hemithioacetal (5–250 μM). (DOC 551 kb)
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